Chakma Justin Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
11
Insider Sells Sum
$7.09M

Insider Activity of Chakma Justin

According to the SEC Form 4 filings, Chakma Justin, being in a position of

  1. Chief Business Officer at ARS Pharmaceuticals, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 166380 shares for $1.48M,
    over all time since 2024-11-25, has bought 0 shares, and sold 695625 shares for $8.56M.

Biography of Chakma Justin

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$000
Sells
$1,476,1471100

Comparison of Insiders on Amount of Buys and Sells

2025-11-12SaleARS Pharmaceuticals, Inc.
SPRY
Chief Business Officer
166,380
0.1707%
$8.87$1.48M-8.49%
2024-12-13SaleARS Pharmaceuticals, Inc.
SPRY
Chief Business Officer
27,272
0.0282%
$12.06$328,969+3.45%
2024-12-12SaleARS Pharmaceuticals, Inc.
SPRY
Chief Business Officer
117,333
0.1186%
$12.27$1.44M-3.05%
2024-12-10SaleARS Pharmaceuticals, Inc.
SPRY
Chief Business Officer
50,000
0.0519%
$13.15$657,625-4.94%
2024-12-06SaleARS Pharmaceuticals, Inc.
SPRY
Chief Business Officer
50,000
0.0517%
$14.23$711,615-11.84%
2024-12-05SaleARS Pharmaceuticals, Inc.
SPRY
Chief Business Officer
49,640
0.0521%
$14.13$701,642-11.25%
2024-12-04SaleARS Pharmaceuticals, Inc.
SPRY
Chief Business Officer
45,000
0.0452%
$13.95$627,944-13.28%
2024-12-03SaleARS Pharmaceuticals, Inc.
SPRY
Chief Business Officer
45,000
0.0452%
$13.19$593,402-7.97%
2024-12-02SaleARS Pharmaceuticals, Inc.
SPRY
Chief Business Officer
45,000
0.0475%
$13.67$615,218-5.78%
2024-11-27SaleARS Pharmaceuticals, Inc.
SPRY
Chief Business Officer
25,000
0.0255%
$14.39$359,750-13.28%
2024-11-26SaleARS Pharmaceuticals, Inc.
SPRY
Chief Business Officer
42,186
0.042%
$14.05$592,570-12.21%
2024-11-25SaleARS Pharmaceuticals, Inc.
SPRY
Chief Business Officer
32,814
0.0326%
$14.00$459,422-7.84%
Total: 12
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.